Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/243515 
Authors: 
Year of Publication: 
2021
Series/Report no.: 
LEM Working Paper Series No. 2021/19
Publisher: 
Scuola Superiore Sant'Anna, Laboratory of Economics and Management (LEM), Pisa
Abstract: 
This note discusses the medical/therapeutical responses to the COVID-19 pandemic and their 'political economy' context. First, the very quick development of several vaccines highlights the richness of the basic knowledge waiting for therapeutical exploitation. Such knowledge has largely originated in public or non-profit institutions. Second, symmetrically, there is longer-term evidence that the private sector (essentially Big Pharma) has decreased its investment in basic research in general, and has long been uninterested in vaccines in particular. Only when flooded with an enormous amount of public money it became eager to undertake applied research, production scale-up and testing. Third, the 'political economy' of the underlying public-private relationship reveals a profound dysfunctionality with the public being unable to determine the rates and direction of innovation, but at the same time confined to the role of payer of first and last resort, with dire consequences for both advanced, and more so, developing countries. Fourth, on normative grounds, measures like ad hoc patent waivers are certainly welcome, but this will not address the fundamental challenge, involving a deep reform of the Intellectual Property Rights regimes and their international protection (TRIPS Agreements).
Subjects: 
Covid-19 pandemic
vaccines
Intellectual property rights
TRPS
innovation
public goods
JEL: 
O31
O34
D63
H41
H51
Document Type: 
Working Paper

Files in This Item:
File
Size
233.33 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.